

# The Metabolic Syndrome Is Frequent in Klinefelter's Syndrome and Is Associated With Abdominal Obesity and Hypogonadism

ANDERS BOJESEN, MD, PHD<sup>1,2</sup>  
 KURT KRISTENSEN, MD, PHD<sup>3</sup>  
 NIELS H. BIRKEBAEK, MD, PHD<sup>3</sup>  
 JENS FEDDER, MD, PHD<sup>4</sup>  
 LEIF MOSEKILDE, MD, DMSCI<sup>5</sup>  
 PAUL BENNETT, MD<sup>6</sup>

PETER LAURBERG, MD, DMSCI<sup>7</sup>  
 JAN FRYSTYK, MD, DMSCI<sup>1</sup>  
 ALLAN FLYVBJERG, MD, DMSCI<sup>1</sup>  
 JENS S. CHRISTIANSEN, MD, DMSCI<sup>1</sup>  
 CLAUS H. GRAVHOLT, MD, DMSCI<sup>1</sup>

tion, primarily through increased truncal fat and decreased muscle mass. Testosterone treatment in Klinefelter's syndrome only partly corrected the unfavorable changes observed in untreated Klinefelter's syndrome, perhaps due to insufficient testosterone doses.

*Diabetes Care* 29:1591–1598, 2006

**OBJECTIVE** — Klinefelter's syndrome is associated with an increased prevalence of diabetes, but the pathogenesis is unknown. Accordingly, the aim of this study was to investigate measures of insulin sensitivity, the metabolic syndrome, and sex hormones in patients with Klinefelter's syndrome and an age-matched control group.

**RESEARCH DESIGN AND METHODS** — In a cross-sectional study, we examined 71 patients with Klinefelter's syndrome, of whom 35 received testosterone treatment, and 71 control subjects. Body composition was evaluated using dual-energy X-ray absorptiometry scans. Fasting blood samples were analyzed for sex hormones, plasma glucose, insulin, C-reactive protein (CRP), and adipocytokines. We analyzed differences between patients with untreated Klinefelter's syndrome and control subjects and subsequently analyzed differences between testosterone-treated and untreated Klinefelter's syndrome patients.

**RESULTS** — Of the patients with Klinefelter's syndrome, 44% had metabolic syndrome (according to National Cholesterol Education Program/Adult Treatment Panel III criteria) compared with 10% of control subjects. Insulin sensitivity (assessed by homeostasis model assessment 2 modeling), androgen, and HDL cholesterol levels were significantly decreased, whereas total fat mass and LDL cholesterol, triglyceride, CRP, leptin, and fructosamine levels were significantly increased in untreated Klinefelter's syndrome patients. In treated Klinefelter's syndrome patients, LDL cholesterol and adiponectin were significantly decreased, whereas no difference in body composition was found in comparison with untreated Klinefelter's syndrome patients. Multivariate analyses showed that truncal fat was the major determinant of metabolic syndrome and insulin sensitivity.

**CONCLUSIONS** — The prevalence of metabolic syndrome was greatly increased, whereas insulin sensitivity was decreased in Klinefelter's syndrome. Both correlated with truncal obesity. Hypogonadism in Klinefelter's syndrome may cause an unfavorable change in body composition,

**K**linefelter's syndrome is the most common sex chromosome disorder, with a prevalence of 1 in 660 men (1), and is a frequent cause of hypogonadism and infertility. It is caused by the presence of extra X chromosomes, the most common karyotype being 47,XXY. The phenotype is variable, but the most constant finding is small hyalinized testes, hypergonadotropic hypogonadism, infertility, eunuchoid body proportion, increased height, and learning disabilities (2).

Previously Klinefelter's syndrome was associated with an increased risk of diabetes, but this association has not been further investigated (3–5). Epidemiological studies on mortality (6) and morbidity in Klinefelter's syndrome (7) have shown an increased risk of dying from diabetes or being admitted to the hospital with diabetes.

Hypogonadism is common in Klinefelter's syndrome and has been found to be an independent risk factor for development of abdominal adiposity in men with normal chromosomes (8). Hypogonadism is also associated with metabolic syndrome and type 2 diabetes (9–11). Experimental induction of hypogonadism and subsequent testosterone substitution showed a dose-dependent change in body composition with changes in fat-free mass being inversely related to increasing testosterone doses (12). Testosterone treatment of middle-aged abdominally obese men decreased the amount of intra-abdominal fat and increased insulin sensitivity (13). Thus, hypogonadism may lead to abdominal adiposity, thereby increasing the risk of metabolic syndrome and development of type 2 diabetes. In a cross-sectional study of adult patients

From the <sup>1</sup>Medical Department M, Endocrinology and Diabetes, and Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Aarhus, Denmark; the <sup>2</sup>Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark; the <sup>3</sup>Department of Pediatrics, Aarhus University Hospital, Skejby Hospital, Aarhus, Denmark; the <sup>4</sup>Fertility Clinic and Scientific Unit, Braedstrup Hospital, Braedstrup, Denmark; <sup>5</sup>Medical Department C, Aarhus University Hospital, Aarhus, Denmark; the <sup>6</sup>Department of Clinical Biochemistry, Statens Serum Institut, Copenhagen, Denmark; and the <sup>7</sup>Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark.

Address correspondence and reprint requests to Anders Bojesen, MD, Medical Department M, Endocrinology and Diabetes, Aarhus University Hospital, Noerrebrogade 42-44, DK-8000, Aarhus C, Denmark. E-mail: anders.bojesen@dadlnet.dk.

Received for publication 20 January 2006 and accepted in revised form 18 April 2006.

**Abbreviations:** ATPIII, Adult Treatment Panel III; BFtr, truncal fat; CRP, C-reactive protein; DEXA, dual-energy X-ray absorptiometry; FPG, fasting plasma glucose; FSH, follicle-stimulating hormone; HOMA, homeostasis model assessment; HOMA2%S, HOMA of insulin sensitivity; IMAT, intermuscular adipose tissue; LBM, lean body mass; LH, luteinizing hormone; NCEP, National Cholesterol Education Program; SHBG, sex hormone-binding globulin; SMM, skeletal muscle mass; TBF, total body fat.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

DOI: 10.2337/dc06-0145

© 2006 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

with Klinefelter's syndrome and an age-matched control group, we investigated the impact of hypogonadism on body composition and other components of the metabolic syndrome, including insulin sensitivity.

## RESEARCH DESIGN AND METHODS

A total of 71 patients with Klinefelter's syndrome were recruited from endocrine and fertility clinics. Inclusion criteria were age >18 years, a verified Klinefelter's syndrome karyotype, and signed informed consent. Exclusion criteria were untreated hypothyroidism or hyperthyroidism, present or past malignant diseases, clinical liver disease, or treatment with drugs knowing to interfere with glucose homeostasis or fat metabolism (e.g., glucocorticoids). One of the Klinefelter's syndrome patients had the 49,XXXXY karyotype and was excluded from the analysis. Thirty-five (50%) of the remaining 70 Klinefelter's syndrome patients received testosterone treatment at the time of investigation (intramuscular testosterone injections [ $n = 20$ ], oral testosterone undecanoate [ $n = 14$ ], and mesterolone [ $n = 1$ ]). Because of the inability of some of the Klinefelter's syndrome patients to recall the date of their last injection and because we did not have access to all patients files, we did not have information about the timing of the last injection of testosterone in the treated Klinefelter's syndrome patients. Of the 35 Klinefelter's syndrome patients without testosterone treatment, 9 had received testosterone treatment in the past but not during the last year before examination. A healthy age-matched control group was recruited by advertising for healthy volunteers at the University of Aarhus and at the Blood Bank at the Aarhus University Hospital. None of the healthy control subjects received any kind of steroid therapy.

All patients received oral and written information concerning the study before giving written informed consent. The protocol was approved by the Aarhus County Ethical Scientific Committee (# 20010155) and the Danish Data Protection Agency.

All participants were examined in the morning after an overnight fast. Blood was drawn, and serum and plasma were immediately separated and stored at  $-20^{\circ}\text{C}$  in multiple vials for later analysis. Body weight was measured (with the participants wearing underwear) to the nearest 0.1 kg, height was measured to the nearest 0.5 cm, BMI was calculated, and

waist and hip circumferences were measured. Blood pressure was measured in the sitting position, using a mercury sphygmomanometer.

Whole-body dual-energy X-ray absorptiometry (DEXA) scans were performed on a Hologic 2000/w osteodensitometer (Hologic, Waltham, MA). Total body fat (TBF), lean body mass (LBM), and truncal fat (BFtr) were calculated as percentages. Intermuscular adipose tissue (IMAT)-free skeletal muscle mass (SMM) was then estimated according to a recently developed, magnetic resonance imaging-based, and validated prediction model with minimal variation (14) as

$$\begin{aligned} \text{IMAT-free SMM} &= -0.14 \\ &+ 1.18 * \text{appendicular LBM} \\ &(\text{in kilograms}) - 0.03 * \text{age} \end{aligned}$$

Because they weighed >130 kg, seven Klinefelter's syndrome patients were not DEXA scanned (weight limit is 130 kg). Another six (four Klinefelter's syndrome patients and two control subjects) were not DEXA scanned because of technical errors. The coefficient of variation (CV) for DEXA scans was <2% from repeated measurements (15).

A maximal oxygen consumption ( $\text{VO}_{2\text{max}}$ ) test was performed on a bicycle ergometer using a standardized protocol. The initial workload was increased with 10 W every 30 s until exhaustion. Breath-by-breath gas exchange analysis was performed; maximal oxygen consumption was determined as the highest  $\text{O}_2$  consumption achieved during exercise with a calorimeter (Jaeger Oxycon Delta; Erich Jaeger, Hoechberg, Germany), and  $\text{VO}_{2\text{max}}$  was calculated. Seventy control subjects and 60 Klinefelter's syndrome patients were able to finish the test; the main reason for not finishing the test was leg pain during exercise.

## Assays

Plasma glucose levels were measured in duplicate immediately after sampling on a glucose analyzer (Beckman Instruments, Palo Alto, CA). Serum insulin was determined by a commercial immunological kit (DAKO, Glostrup, Denmark). Androgens, estrogens, sex hormone-binding globulin (SHBG), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were analyzed as described (16). We estimated free testosterone by a method described by Bartsch (17), based on measurement of SHBG, total testosterone, and

dihydrotestosterone, using the law of mass action and the binding constant of testosterone and dihydrotestosterone to SHBG, including a calculation of testosterone binding to albumin (assuming a constant association constant to albumin). In this system, binding to cortisol-binding globulin is thought to be negligible. The method we used to estimate free testosterone is essentially similar to the method suggested by Vermeulen et al. (18) to be the most reliable and correlates closely with direct measurement of free testosterone by equilibrium dialysis. Plasma lipids and triglycerides were measured using an automated commercially available system (Aeroset; Abbott Diagnostics); CVs were <5%. C-reactive protein (CRP) was measured by an ultrasensitive assay (Diagnostic Products, Los Angeles, CA). Serum adiponectin was determined by a novel in-house time-resolved immunofluorometric assay as previously described (19), leptin was determined by a commercial radioimmunoassay (Linco, St. Louis, MO), and serum fructosamine was analyzed by a commercial colorimetric assay (Horiba ABX Diagnostics, Montpellier, France).

## Classification of impaired fasting glycemia, diabetes, and metabolic syndrome

We defined metabolic syndrome, in accordance with the definition of the National Cholesterol Education Program (NCEP)/Adult Treatment Panel III (ATPIII), as the presence of three or more of the following criteria: fasting plasma glucose (FPG) >6.1 mmol/l, serum triglyceride >1.7 mmol/l, serum HDL cholesterol <1.0 mmol/l, blood pressure >130/85 mmHg or use of antihypertensive medication, or waist circumference >102 cm (20). A diabetic FPG level was defined as FPG >7 mmol/l; impaired fasting glycemia was defined as FPG between 6.1 and 7.0 mmol/l according to World Health Organization criteria.

## Calculation of insulin sensitivity

Insulin sensitivity (%S) and  $\beta$ -cell function were assessed by homeostasis model assessment (HOMA) modeling (21,22), which is based on simultaneously sampled fasting levels of glucose and insulin. The relationship between glucose and insulin in the fasting state reflects the balance between hepatic glucose output and insulin secretion (22). The HOMA2 computer model was downloaded from <http://>

www.dtu.ox.ac.uk/index.html?maindoc=/homa/download.html.

## Statistics

Because the group of testosterone-treated Klinefelter's syndrome patients was very heterogenic with regard to testosterone levels and because we had no valid information on timing of the last intramuscular injection of testosterone, we performed the analyses in two steps. First, we compared the untreated Klinefelter's syndrome patients with the control group and then the untreated Klinefelter's syndrome patients with the testosterone-treated Klinefelter's syndrome patients.

Apart from height,  $VO_{2max}$ , and the ratio between  $17\beta$ -estrogen and testosterone, none of the variables were normally distributed, and nonparametric tests were used to test for differences between groups. All results are shown as medians and total range. Spearman correlation analysis was used to describe correlations between variables to select principal-independent variables for later use in regression analyses. Stepwise multivariate regression analysis was used to evaluate the impact of independent variables on the dependent variables (metabolic syndrome [i.e., an individual being classified as having it or not], insulin sensitivity,  $VO_{2max}$ , and body composition), with inclusion of status (i.e., being a Klinefelter's syndrome patient or a control subject) as a dummy variable. Multivariate analysis was performed on the whole group of participants, including both treated and untreated Klinefelter's syndrome patients as well as the control subjects. The significance levels for entering and for removal of variables from the model were  $P < 0.05$  and  $P < 0.10$ , respectively. Log transformation of variables was used when appropriate. Logistic regression analysis was used to evaluate the impact of variables on the dichotomous variable "metabolic syndrome." All statistics were calculated using intercooled STATA (V8.2; StataCorp, College Station, TX).  $P$  values  $< 0.05$  were regarded as significant.

## RESULTS

### Untreated Klinefelter's syndrome patients versus healthy control subjects

**Anthropometry.** The two groups were matched by age and height. Weight, BMI, waist, TBF, and BFtr were all significant greater in Klinefelter's syndrome patients,

whereas IMAT-free SMM was significantly decreased in Klinefelter's syndrome patients compared with healthy control subjects (Table 1).

**Diabetes and the metabolic syndrome.** In the Klinefelter's syndrome patients, all the measures of insulin sensitivity and metabolic syndrome except blood pressure were changed in a pathologic direction; fasting serum insulin and fasting plasma glucose were higher among the Klinefelter's syndrome patients, whereas insulin sensitivity (HOMA2%S) was significantly reduced. Total cholesterol, LDL cholesterol, and triglycerides were all significantly increased, and HDL cholesterol was significantly decreased in Klinefelter's syndrome patients. CRP and leptin levels were higher in Klinefelter's syndrome patients, whereas levels of adiponectin and fructosamine were similar between the two groups. With the NCEP/ATPIII criteria, 16 of the 35 Klinefelter's syndrome patients (46%) and 7 control subjects (9.9%) had metabolic syndrome ( $P < 0.001$ ), 3 Klinefelter's syndrome patients (9%), and 1 control subject (1.4%) had diabetic FPG levels ( $P = 0.10$ ), and 6 Klinefelter's syndrome patients (17%) and 2 control subjects (3%) had impaired fasting glycemia ( $P = 0.02$ ).

**Sex hormones.** Testosterone, free testosterone, and SHBG were significantly reduced, and FSH, LH, and the ratio between  $17\beta$ -estrogen and testosterone were significantly increased in Klinefelter's syndrome patients. There was no significant difference in  $17\beta$ -estrogen.

**Exercise testing.** Klinefelter's syndrome patients had significantly lower maximal oxygen uptake.

### Testosterone-treated Klinefelter's syndrome patients versus untreated Klinefelter's syndrome patients

**Anthropometry.** We found no difference in any anthropometric measures between the groups, although TBF ( $P = 0.08$ ) and BFtr ( $P = 0.11$ ) tended to be lower in the testosterone-treated Klinefelter's syndrome group (Table 1).

**Diabetes and the metabolic syndrome.** A significantly lower level of LDL cholesterol was found in the testosterone-treated Klinefelter's syndrome group. Total cholesterol, fasting glucose CRP, and leptin levels tended to be lower in the testosterone-treated Klinefelter's syndrome group, whereas no difference in HOMA2%S or frequency of diabetes or

metabolic syndrome was found. Adiponectin was, however, significantly lower in the testosterone-treated Klinefelter's syndrome group.

**Sex hormones.** FSH and LH were significantly lower, whereas  $17\beta$ -estrogen was significantly higher in the testosterone-treated Klinefelter's syndrome group. No differences in testosterone, free testosterone, SHBG, or  $17\beta$ -estrogen-to-testosterone ratio were found between the groups.

**Exercise testing.** No difference was found between the groups.

### All participants

We then studied all participants in univariate regression and multiple regression models. We first studied Klinefelter's syndrome patients and control subjects separately in univariate analyses, and subsequently combined treated and untreated Klinefelter's syndrome patients and control subjects in multivariate models in an attempt to identify factors contributing to the observed differences in insulin sensitivity, BFtr, SMM,  $VO_{2max}$ , and the dichotomous variable metabolic syndrome between groups.

### Associations between sex hormones and variables related to the metabolic syndrome

HOMA2%S correlated significantly with testosterone (Klinefelter's syndrome  $r = 0.31$ ,  $P = 0.01$ ; control  $r = 0.28$ ,  $P = 0.02$ ) and BFtr (Klinefelter's syndrome  $r = -0.70$ ,  $P < 0.0001$ ; control  $r = -0.52$ ,  $P < 0.0001$ ) (Fig. 1). It also correlated with SHBG, CRP, adiponectin, BMI, IMAT-free SMM, TBF, and  $VO_{2max}$  (results not shown).


BFtr correlated significantly with leptin (Klinefelter's syndrome  $r = 0.89$ ,  $P < 0.0001$ ; control  $r = 0.84$ ,  $P < 0.0001$ ), testosterone (Klinefelter's syndrome  $r = -0.43$ ,  $P = 0.0007$ ; control  $r = -0.43$ ,  $P = 0.0002$ ), and CRP (Klinefelter's syndrome  $r = 0.47$ ,  $P = 0.0002$ ; control  $r = 0.29$ ,  $P = 0.02$ ) (Fig. 1). It also correlated with free testosterone, SHBG, age, adiponectin, and  $VO_{2max}$  (results not shown).

$VO_{2max}$  correlated significantly with age (Klinefelter's syndrome  $r = -0.30$ ,  $P = 0.03$ ; control  $r = -0.59$ ,  $P < 0.0001$ ) and IMAT-free SMM (Klinefelter's syndrome  $r = 0.49$ ,  $P = 0.0003$ ; control  $r = 0.36$ ,  $P = 0.003$ ) (Fig. 1). It also correlated with free testosterone, CRP, leptin, and BFtr (results not shown).

Table 1—Number and age of participants, median (range) of anthropometric data, DEXA-derived body composition data, sex hormones, measures of the metabolic syndrome, insulin sensitivity and frequency of metabolic syndrome and diabetes in untreated Klinefelter's syndrome (U-KS) patients, testosterone-treated Klinefelter's syndrome patients (T-KS), and normal men

	U-KS		T-KS	Control subjects		P value	
	n	U-KS	T-KS	Control subjects	U-KS vs. control subjects*	U-KS vs. T-KS*	
n	35	35	35	71			
Age (years)	35.0 (19.0–66.2)	38.7 (19.3–62.3)	38.7 (19.2–68.0)	36.4 (19.2–68.0)	0.95	0.82	
Height (cm)	183.6 ± 9.16	185.4 ± 8.02	181.1 ± 5.67	181.1 ± 5.67	0.09†	0.39†	
Weight (kg)	92.5 (56.8–183)	85.0 (65.8–150)	82.5 (60.1–127.5)	82.5 (60.1–127.5)	0.0008	0.56	
BMI (kg/m <sup>2</sup> )	27.3 (20.0–60.6)	25.1 (18.1–54.7)	24.9 (19.0–36.9)	24.9 (19.0–36.9)	0.008	0.37	
Waist (cm)	109 (81–179)	104 (75.0–175)	92 (76–133)	92 (76–133)	<0.0001	0.27	
VO <sub>2max</sub> (ml O <sub>2</sub> · kg <sup>-1</sup> · min <sup>-1</sup> )	30.6 ± 7.13	31.0 ± 9.9	44.1 ± 10.8	44.1 ± 10.8	<0.0001†	0.83†	
BFtr (%)	34.0 (10.1–49.3)	23.2 (2.45–56.2)	17.6 (3.22–43.7)	17.6 (3.22–43.7)	<0.0001	0.11	
Body fat (%)	28.8 (12.5–42.4)	22.2 (7.88–45.0)	18.4 (6.16–37.3)	18.4 (6.16–37.3)	<0.0001	0.08	
IMAT-free SMM (kg)	31.9 ± 4.02	32.6 ± 4.15	34.2 ± 4.40	34.2 ± 4.40	0.01†	0.50†	
Testosterone (T) (nmol/l)	12.7 (0.75–37.3)	14.0 (1.88–72.2)	21.8 (10.6–55.5)	21.8 (10.6–55.5)	<0.0001	0.19	
Free testosterone (nmol/l)	0.33 (0.01–0.66)	0.33 (0.06–2.60)	0.53 (0.17–1.37)	0.53 (0.17–1.37)	<0.0001	0.15	
SHBG (nmol/l)	31 (16–79)	29 (13–87)	36 (17–99)	36 (17–99)	0.04	0.38	
17β-estradiol (E <sub>2</sub> ) (pmol/l)	77 (40–140)	89 (44–290)	81 (40–210)	81 (40–210)	0.82	0.04	
E <sub>2</sub> /T ratio	10.3 ± 2.06	8.68 ± 1.44	3.78 ± 0.18	3.78 ± 0.18	<0.0001	0.52	
FSH (IU/l)	27.7 (1.90–49.2)	14.3 (0.2–49.3)	3.3 (0.6–46)	3.3 (0.6–46)	<0.0001	0.01	
LH (IU/l)	17.2 (1.0–27.4)	9.1 (0.60–22.2)	3.4 (1.4–22.3)	3.4 (1.4–22.3)	<0.0001	0.0001	
Triglycerides (mmol/l)	1.48 (0.41–40.2)	1.64 (0.63–5.61)	0.82 (0.40–2.46)	0.82 (0.40–2.46)	0.0001	0.72	
Total cholesterol (mmol/l)	5.84 (3.70–13.5)	5.16 (3.78–7.36)	4.66 (3.34–7.38)	4.66 (3.34–7.38)	0.002	0.07	
LDL cholesterol (mmol/l)	3.75 (2.0–5.14)	3.30 (2.15–4.74)	3.0 (1.68–5.49)	3.0 (1.68–5.49)	0.004	0.04	
HDL cholesterol (mmol/l)	1.01 (0.52–2.20)	0.95 (0.61–1.92)	1.29 (0.77–2.55)	1.29 (0.77–2.55)	0.0001	0.33	
Plasma glucose (mmol/l)	5.5 (4.8–10.2)	5.3 (4.0–10.4)	5.1 (4.2–8.2)	5.1 (4.2–8.2)	<0.0001	0.08	
Serum insulin (pmol/l)	66.5 (15–270)	54 (13–420)	36 (9–136)	36 (9–136)	0.0001	0.89	
HOMA2-B (%)	88.1 (39.7–240)	94.8 (44.0–291)	73.8 (33.1–180)	73.8 (33.1–180)	0.10	0.28	
HOMA2%S (%)	68.4 (17.7–301)	84.8 (11.7–359)	128 (34.4–514)	128 (34.4–514)	<0.0001	0.70	
CRP (mg/dl)	0.21 (0.03–2.74)	0.17 (0.02–1.83)	0.11 (0.02–1.99)	0.11 (0.02–1.99)	0.0005	0.10	
Leptin (ng/ml)	14.0 (2.41–116)	8.44 (1.51–75.2)	3.07 (1.24–17.0)	3.07 (1.24–17.0)	<0.0001	0.08	
Fructosamine (μmol/l)	274 (230–373)	279 (237–386)	271 (230–380)	271 (230–380)	0.17	0.26	
Adiponectin (mg/l)	9.10 (3.78–18.1)	6.97 (3.0–24.2)	7.37 (3.14–22.2)	7.37 (3.14–22.2)	0.31	0.05	
Metabolic syndrome (%)	46 (16/35)	49 (17/35)	10 (7/71)	10 (7/71)	<0.001‡	0.73‡	
Diabetes (%)	9 (3/35)	11 (4/35)	1 (1/71)	1 (1/71)	0.10§	0.71§	
Impaired fasting glycemia (%)	17 (6/35)	20 (7/35)	3 (2/71)	3 (2/71)	0.02§	0.72§	

Data are medians (total range) or means ± SD. \*Mann-Whitney rank-sum test. †Student's t test. ‡χ<sup>2</sup> test. §Fisher's exact test. HOMA2-B, β-cell function estimated by HOMA2 modeling.



**Figure 1**—A: BFtr in correlation with BMI. Klinefelter's syndrome patients (KS, ○) have more BFtr (~8% more) for any value of BMI than control subjects (C, ●). (No formal testing for differences between the two regression lines was performed, but CIs for interception with the y-axis were not overlapping, indicating a significant difference.) B: Insulin sensitivity (lnHOMA2S) in relation to truncal fat. Klinefelter's syndrome patients (○) and control subjects (●) show the same negative correlation between insulin sensitivity and BFtr. C: VO<sub>2</sub>max in relation to IMAT-free SMM. Klinefelter's syndrome patients (○) have less maximal oxygen uptake (VO<sub>2</sub>max) for any value of IMAT-free SMM than control subjects (●).

### Multivariate models to predict independent variables of the metabolic syndrome

BFtr ( $r = -0.57$ ,  $P < 0.0001$ ) and SHBG ( $r = 0.23$ ,  $P = 0.001$ ) were the only independent variables accounting for 48% of the variance in HOMA2%S, whereas status (i.e., having Klinefelter's syndrome or not), testosterone, CRP, adiponectin, leptin, and IMAT-free SMM did not enter the model. In contrast, in a similar analysis, Klinefelter's syndrome ( $r = -0.42$ ,  $P < 0.0001$ ) along with IMAT-free SMM ( $r = 0.31$ ,  $P < 0.0001$ ), BFtr ( $r = -0.20$ ,  $P = 0.005$ ), and age ( $r = -0.30$ ,  $P < 0.0001$ ) accounted for 56% of the variance of  $VO_{2max}$ .

In a model with BFtr as the dependent variable, leptin ( $r = 0.61$ ,  $P < 0.0001$ ), age ( $r = 0.2$ ,  $P < 0.0001$ ),  $VO_{2max}$  ( $r = -0.24$ ,  $P < 0.0001$ ), adiponectin ( $r = -0.10$ ,  $P = 0.004$ ), and SHBG ( $r = -0.16$ ,  $P = 0.002$ ) accounted for 80% of the variance, excluding Klinefelter's syndrome status, testosterone, free testosterone, and CRP from the model. Finally, in a logistic regression model with the dichotomous variable metabolic syndrome as the dependent variable, BFtr was the only independent predictor (odds ratio = 1.23,  $P < 0.0001$ ), excluding testosterone, free testosterone, SHBG, status (Klinefelter's syndrome or not), CRP, leptin, adiponectin, age, and  $VO_{2max}$  from the model.

**CONCLUSIONS**— The main result of the present study is the strikingly increased frequency of the metabolic syndrome in Klinefelter's syndrome, with a high occurrence of increased body fat, waist circumference, insulin resistance, and increased LDL cholesterol and CRP levels, but with apparently normal blood pressure and, paradoxically, a normal level of adiponectin. The strongest predictor of the metabolic syndrome was adiposity and especially BFtr. For any given BMI value, Klinefelter's syndrome patients have higher percentage of BFtr than control subjects, even in the normal range of BMI (Fig. 1A). Although Becker et al. (23) in 1966 stated that 50% of their 50 Klinefelter's syndrome patients were obese (but slim during their adolescence), the typical man with Klinefelter's syndrome has always been described as tall and slim, with narrow shoulders and long arms and legs. In contrast to this dogmatic picture, we found a dramatic change in body composition in Klinefelter's syndrome patients compared with normal control subjects.

Hypogonadism in Klinefelter's syndrome is relative rather than absolute. The median total testosterone level was in the low-normal range but was substantially and significantly lower than the testosterone level in the control subjects, similar to previous findings (24), with reciprocally increased levels of LH and FSH (24,25), clearly illustrating that these Klinefelter's syndrome patients are hypogonadal. In contrast to some reports (25–27) but in accordance with others (24), SHBG was significantly lower and  $17\beta$ -estradiol was normal in Klinefelter's syndrome patients.

Almost half of the Klinefelter's syndrome patients fulfilled the NCEP/ATPIII criteria for the metabolic syndrome, whereas only 10% of the control subjects did, even though no difference in blood pressure was detected. Plasma lipids were increased, except for HDL cholesterol, which was reduced. A prospective study of Japanese-American men showed that those with testosterone levels in the lower quartile had a 2.3-fold increased risk of developing metabolic syndrome (10), somewhat lower than the ~5 times elevated risk in our study. Klinefelter's syndrome patients had a higher frequency of impaired fasting glycemia and diabetes. This corresponds with the report of Nielsen et al. in 1969 (4), who found diabetic results for oral glucose tolerance tests in 39% of their Klinefelter's syndrome patients. Calculation of insulin sensitivity by the HOMA model showed a significant decrease in Klinefelter's syndrome patients but a significant increase in  $\beta$ -cell function, which reflects the fact that the Klinefelter's syndrome patients indeed are insulin resistant and compensate with increased production of insulin. This is partially in contrast to a recent report in which fasting hyperinsulinemia was present but with a nonsignificant decrease in insulin sensitivity (5). The participants in that study were young (22 years) and fairly lean (BMI 24 kg/m<sup>2</sup>), and the study may have been underpowered. Pei et al. (3) found that Klinefelter's syndrome patients ( $n = 7$ ) as well as hypogonadotropic hypogonadal patients ( $n = 7$ ) were insulin resistant and hyperinsulinemic as judged by an insulin sensitivity test and oral glucose tolerance test. Nevertheless, we find it quite striking to uncover such a high incidence of the metabolic syndrome.

CRP, a marker of low-grade inflammation and a predictor of cardiovascular disease (28), was significantly increased

in Klinefelter's syndrome patients. This is in concert with a cross-sectional study on middle-aged nondiabetic men, in which testosterone, free testosterone, and SHBG had an inverse correlation with CRP (29). Adiponectin has been reported to be inversely correlated to obesity (30); however, in the present study, the level of adiponectin in Klinefelter's syndrome was comparable to that of control subjects, which may be explained by the concomitant hypogonadism that has been shown to increase the level of adiponectin independently of BMI (31). Further, testosterone treatment has been shown to normalize (decrease) adiponectin (31–33), and likewise we found a significantly lower level of adiponectin in treated compared with untreated Klinefelter's syndrome patients. Whether the increased amount of adiponectin may counteract the other risk factors seen in Klinefelter's syndrome (increased CRP, total cholesterol, and decreased HDL cholesterol levels) is unknown. Epidemiological studies on mortality in Klinefelter's syndrome have shown an increased risk of dying from circulatory diseases (34,35) but not ischemic heart disease (34). Leptin is also correlated to the amount of body fat (36), and we found a tremendous increase in the Klinefelter's syndrome patients, probably reflecting their increased TBF. Maximal oxygen uptake was diminished in Klinefelter's syndrome patients, and, in multivariate analysis, it correlated negatively to BFtr, diagnosis of Klinefelter's syndrome,  $17\beta$ -estradiol, and age but positively correlated to the IMAT-free SMM. Decreased LBM (which partially reflects muscle mass) has been described in hypogonadal states, and testosterone treatment can increase LBM, muscle size (12,37), and strength (12). The effect of hypogonadism on  $VO_{2max}$  and, thus, on physical fitness may be operative through several mechanisms; the decrease in muscle mass and increase in fat mass makes physical activity more difficult, and a well-known symptom in hypogonadal states is fatigue, which in turn makes exercise even more difficult. In the multivariate analysis, Klinefelter's syndrome status itself was the strongest (negative) predictor of  $VO_{2max}$ , followed by SMM. Remarkably, for any given size of SMM, Klinefelter's syndrome patients had a significantly lower  $VO_{2max}$  (Fig. 1C).

In multivariate analyses, BFtr was the independent variable with the most significant impact on both the metabolic syndrome and measures of insulin sensi-

tivity. When controlling for BFtr, the impact of hypogonadism on the presence of the metabolic syndrome or not and on insulin sensitivity disappeared. This result supports previous findings in type 2 diabetic patients and healthy volunteers by Abate et al. (38) and Tsai et al. (39) who both found that measures of insulin resistance, hepatic glucose output, and insulin secretion were not dependent on sex hormone levels after controlling for upper body obesity.

Because of the cross-sectional design of this study, we cannot determine the order of events that eventually lead to increased incidence of metabolic syndrome in Klinefelter's syndrome. Whether increased TBF precedes the hypogonadal state in Klinefelter's syndrome is speculative and probably not likely, and it seems more plausible that the hypogonadal state and increased TBF are both part of a vicious cycle in Klinefelter's syndrome. However, although the cross-sectional nature precludes most conclusions on causality, the fact that the parameter "Klinefelter's syndrome status" in a multiple linear regression model of  $VO_{2max}$  is a significant contributor to the observed differences between Klinefelter's syndrome and control subjects shows that the genotype, i.e., having Klinefelter's syndrome, does explain a part of the observed differences. The consequences of a given genotype materialize long before the present measurements and can be viewed as a stable marker of host susceptibility, enabling one to draw conclusions regarding causality even from a studies with a cross-sectional design (40).

When comparing the group of testosterone-treated with untreated Klinefelter's syndrome patients, we did not find dramatic differences. The only significant differences found were decreases in FSH, LH, LDL cholesterol, and adiponectin and an increase in  $17\beta$ -estradiol. The amount of body fat tended to be lower as did fasting plasma glucose, total cholesterol, leptin, and CRP. An explanation for this unexpected lack of difference could be the use of inadequate low doses of testosterone, reflected by the lack of difference in testosterone or free testosterone between the treated and untreated groups of Klinefelter's syndrome patients and the inability to suppress FSH and LH to normal values. The higher levels of  $17\beta$ -estrogen in the testosterone-treated Klinefelter's syndrome group could be caused by an increased aromatase activity. Supporting this hypothesis is the signifi-

cantly higher ratio between  $17\beta$ -estrogen and testosterone in the untreated Klinefelter's syndrome group compared with control subjects although the absolute level of  $17\beta$ -estrogen is not increased. The decrease in adiponectin in the testosterone-treated Klinefelter's syndrome group is a potentially adverse effect of testosterone treatment, but whether this rather negative effect of testosterone treatment is counterbalanced by the concomitant reduction in LDL and total cholesterol, fat mass, and fasting glucose is currently unknown. Although not proven from this or other studies, it seems reasonable that testosterone supplementation should be offered to almost all patients with Klinefelter's syndrome.

In summary, we describe for the first time the severe magnitude of the metabolic syndrome in Klinefelter's syndrome. A number of components of the metabolic syndrome are present in Klinefelter's syndrome, but, notably, normal blood pressure was found. Significant truncal obesity was present. Hypogonadism is frequent in Klinefelter's syndrome, and we recommend that all patients with Klinefelter's syndrome should be treated properly with testosterone substitution. However, prospective randomized studies are needed to prove the postulated efficacy of testosterone supplementation in preventing the occurrence of the metabolic syndrome.

**Acknowledgments**—A.B. received financial support through a research fellowship from the University of Aarhus. The study was also supported by grants from the Danish Health Research Council (Grant 9600822, Aarhus University-Novo Nordisk Centre for Research in Growth and Regeneration), the Aase and Einar Danielsen Foundation, and the Danish Diabetes Association.

The technical assistance of Lone Svendsen, Lene Christensen, Susanne Sørensen, Hanne Petersen, Hanne Mertz, Joan Hansen (medical research laboratories), and the staff at the osteoporosis clinic, Aarhus University Hospital, is highly appreciated. We also thank the doctors who referred their Klinefelter's syndrome patients to us.

## References

1. Bojesen A, Juul S, Gravholt CH: Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. *J Clin Endocrinol Metab* 88:622–626, 2003
2. Smyth CM, Bremner WJ: Klinefelter syndrome. *Arch Intern Med* 158:1309–1314, 1998

3. Pei D, Sheu WH, Jeng CY, Liao WK, Fuh MM: Insulin resistance in patients with Klinefelter's syndrome and idiopathic gonadotropin deficiency. *J Formos Med Assoc* 97:534–540, 1998
4. Nielsen J, Johansen K, Yde H: Frequency of diabetes mellitus in patients with Klinefelter's syndrome of different chromosome constitutions and the XYY syndrome: plasma insulin and growth hormone level after a glucose load. *J Clin Endocrinol Metab* 29:1062–1073, 1969
5. Yesilova Z, Oktenli C, Sanisoglu SY, Musabak U, Cakir E, Ozata M, Dagalp K: Evaluation of insulin sensitivity in patients with Klinefelter's syndrome: a hyperinsulinemic euglycemic clamp study. *Endocrine* 27:11–16, 2005
6. Swerdlow AJ, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA: Mortality in patients with Klinefelter syndrome in Britain: a cohort study. *J Clin Endocrinol Metab* 90:6516–6522, 2005
7. Bojesen A, Juul S, Birkebaek NH, Gravholt CH: Morbidity in Klinefelter syndrome; a Danish register study based on hospital discharge diagnoses. *J Clin Endocrinol Metab* 91:1254–1260, 2006
8. Tsai EC, Boyko EJ, Leonetti DL, Fujimoto WY: Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. *Int J Obes Relat Metab Disord* 24:485–491, 2000
9. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB: Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. *Diabetes Care* 23:490–494, 2000
10. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuominen TP, Valkonen VP, Salonen R, Salonen JT: Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. *Diabetes Care* 27:1036–1041, 2004
11. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL: Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. *Diabetes Care* 25:55–60, 2002
12. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW: Testosterone dose-response relationships in healthy young men. *Am J Physiol* 281:E1172–E1181, 2001
13. Marin P, Holmang S, Jonsson L, Sjöström L, Kvist H, Holm G, Lindstedt G, Björntorp P: The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. *Int J Obes Relat Metab Disord* 16:991–997, 1992

14. Kim J, Heshka S, Gallagher D, Kotler DP, Mayer L, Albu J, Shen W, Freda PU, Heymsfield SB: Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults. *J Appl Physiol* 97:655–660, 2004
15. Abrahamsen B, Gram J, Hansen TB, Beck-Nielsen H: Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements. *Bone* 16:385–390, 1995
16. Lykkesfeldt G, Bennett P, Lykkesfeldt AE, Micic S, Moller S, Svenstrup B: Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. *Clin Endocrinol (Oxf)* 23:385–393, 1985
17. Bartsch W: Interrelationships between sex hormone-binding globulin and testosterone, 5 $\alpha$ -dihydrotestosterone and oestradiol-17 $\beta$  in blood of normal men. *Maturitas* 2:109–118, 1980
18. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab* 84:3666–3672, 1999
19. Frystyk J, Tarnow L, Krarup HT, Parving HH, Flyvbjerg A: Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. *Diabetologia* 48:1911–1918, 2005
20. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 285:2486–2497, 2001
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28:412–419, 1985
22. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. *Diabetes Care* 27:1487–1495, 2004
23. Becker KL, Hoffman DL, Underdahl LO, Mason HL: Klinefelter's syndrome: clinical and laboratory findings in 50 patients. *Arch Intern Med* 118:314–321, 1966
24. Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E: Klinefelter's syndrome. *Lancet* 364:273–283, 2004
25. Wang C, Baker HW, Burger HG, De Kretser DM, Hudson B: Hormonal studies in Klinefelter's syndrome. *Clin Endocrinol (Oxf)* 4:399–411, 1975
26. Forti G, Giusti G, Borghi A, Pazzagli M, Fiorelli G, Cabresi E, Mannelli M, Bassi F, Giannotti P, Fusi S, Serio M: Klinefelter's syndrome: a study of its hormonal plasma pattern. *J Endocrinol Invest* 1:149–154, 1978
27. Wieland RG, Zorn EM, Johnson MW: Elevated testosterone-binding globulin in Klinefelter's syndrome. *J Clin Endocrinol Metab* 51:1199–1200, 1980
28. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. *Circulation* 99:237–242, 1999
29. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT: Sex hormones, inflammation and the metabolic syndrome: a population-based study. *Eur J Endocrinol* 149:601–608, 2003
30. Diez JJ, Iglesias P: The role of the novel adipocyte-derived hormone adiponectin in human disease. *Eur J Endocrinol* 148:293–300, 2003
31. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E: Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. *Clin Endocrinol (Oxf)* 60:500–507, 2004
32. Page ST, Herbst KL, Amory JK, Coviello AD, Anawalt BD, Matsumoto AM, Bremner WJ: Testosterone administration suppresses adiponectin levels in men. *J Androl* 26:85–92, 2005
33. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS: Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. *J Biol Chem* 280:18073–18080, 2005
34. Swerdlow AJ, Hermon C, Jacobs PA, Alberman E, Beral V, Daker M, Fordyce A, Youngs S: Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: a cohort study. *Ann Intern Med* 65:177–188, 2001
35. Bojesen A, Juul S, Birkebaek N, Gravholt CH: Increased mortality in klinefelter syndrome. *J Clin Endocrinol Metab* 89:3830–3834, 2004
36. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. *Nature* 395:763–770, 1998
37. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R: Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. *J Clin Endocrinol Metab* 82:407–413, 1997
38. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM: Sex steroid hormones, upper body obesity, and insulin resistance. *J Clin Endocrinol Metab* 87:4522–4527, 2002
39. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ: Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. *Diabetes Care* 27:861–868, 2004
40. Khoury MJ: Genetic epidemiology. In *Modern Epidemiology*. Rothman KJ, Greenland S, Eds. Philadelphia, Lippincott-Raven, 1998, p. 609–621